Renal & Urinary

Urinary incontinence in adults: types and management

Clinical Overview and When to Suspect Urinary Incontinence

— Stress UI: leakage with cough/laugh/exertion → urethral sphincter weakness or hypermobility (multiparous women, post-prostatectomy men)

— Urge UI / overactive bladder: sudden urgency, often with nocturia → detrusor overactivity

— Mixed UI: features of both; most common pattern in older women

— Overflow UI: continuous dribbling, hesitancy, weak stream → outlet obstruction (BPH) or detrusor underactivity (diabetic neuropathy, anticholinergic burden)

— Functional UI: intact urinary tract but cognitive/mobility barriers (dementia, arthritis, restraints)

— Any woman ≥65, postmenopausal, multiparous, or with pelvic surgery

— Men post-TURP, post-radical prostatectomy, or with BPH symptoms

— Frail elders, dementia, Parkinson disease, stroke, spinal cord pathology, diabetes, multiple sclerosis

— Patients on diuretics, alpha-blockers (in women), sedatives, or new SSRIs

Board pearl: Before labeling chronic incontinence, always exclude reversible DIAPPERS triggers—a new-onset leak in a 78-year-old is a UTI or impaction until proven otherwise, not "just aging." Step 3 stems frequently hinge on catching the reversible cause before committing to chronic therapy.

Definition: involuntary leakage of urine sufficient to be a social or hygienic problem; affects ~25–45% of community-dwelling women and ~10–35% of men, rising sharply after age 65

Why it matters on Step 3: incontinence is under-reported by patients and under-asked by clinicians; it is a USPSTF-relevant geriatric quality measure and a major driver of nursing home placement, falls, skin breakdown, depression, and caregiver burden

Major subtypes to anchor on:

When to actively screen:

DIAPPERS mnemonic for reversible causes: Delirium, Infection (UTI), Atrophic vaginitis, Pharmaceuticals, Psychiatric (depression), Excess output (CHF, hyperglycemia, hypercalcemia), Restricted mobility, Stool impaction

Presentation Patterns and Key History

— Stress: "leaks when I sneeze, lift my grandchild, jump on the trampoline"; small-volume leakage; dry at night

— Urge: "key-in-the-door" or running-water triggers; large-volume accidents; nocturia ≥2; urgency precedes loss

— Overflow: dribbling, sensation of incomplete emptying, straining, nocturnal enuresis in a man with BPH

— Continuous leakage: consider vesicovaginal or ureterovaginal fistula (recent pelvic surgery, obstetric trauma, pelvic radiation)

— Onset, frequency, pad count per day, nocturia episodes

— Fluid pattern: caffeine, alcohol, evening fluid loading

— Obstetric/gynecologic: parity, vaginal vs cesarean delivery, episiotomy, prolapse symptoms ("bulge"), menopausal status, GSM symptoms

— Urologic: prior prostate surgery, pelvic radiation, recurrent UTIs, hematuria

— Neurologic: stroke, MS, Parkinson, spinal cord injury, cauda equina red flags (saddle anesthesia, bowel incontinence, leg weakness)

— Medications: diuretics (loop > thiazide), alpha-blockers, anticholinergics, opioids, calcium-channel blockers, sedatives, gabapentinoids, SGLT2 inhibitors (polyuria, GU infections)

— Functional: gait aids, toilet accessibility, caregiver availability

Step 3 management: When a stem gives you a vague "leaks urine" complaint in clinic, your first orders are a bladder diary, urinalysis, and post-void residual—not urodynamics, not cystoscopy. Empiric behavioral therapy can begin the same visit; specialist referral is reserved for refractory, hematuric, or neurologic cases.

Open the visit with a normalizing question: "Many of my patients leak urine—do you?" Direct questioning roughly doubles disclosure rates versus open-ended review of systems

Symptom-based subtype clues:

Critical history elements:

3-day bladder diary is the single highest-yield outpatient tool—records voids, leaks, triggers, and intake volumes

Physical Exam Findings and Bedside Maneuvers

— Cognition (Mini-Cog), gait and timed-up-and-go, dexterity for clothing manipulation

— Volume status: peripheral edema suggests nocturnal mobilization → nocturia

— BMI (obesity worsens stress UI; weight loss of 5–10% improves continence)

— Atrophic vaginitis / genitourinary syndrome of menopause: pale, thin, friable mucosa, loss of rugae → treat with vaginal estrogen

— Pelvic organ prolapse: cystocele, rectocele, uterine descent (POP-Q staging); have patient Valsalva

— Cough stress test: with comfortably full bladder in lithotomy or standing, ask patient to cough—immediate leak = stress UI; delayed leak after several seconds = cough-triggered detrusor overactivity

— Q-tip test (urethral hypermobility): angle change >30° with Valsalva supports stress UI

— Pelvic floor tone and ability to perform a Kegel contraction

— DRE: prostate size, nodules, sphincter tone

— Phimosis, meatal stenosis, scrotal/inguinal exam

Key distinction: A positive cough stress test plus urethral hypermobility in a parous woman essentially nails stress UI and lets you skip urodynamics before offering pelvic floor therapy or a midurethral sling. By contrast, abnormal neuro exam, hematuria, recurrent UTIs, prior pelvic radiation, or suspected fistula is a hard stop—refer to urology/urogynecology before empiric therapy.

General and functional assessment:

Abdominal exam: suprapubic dullness/fullness suggests retention; palpable bladder = consider overflow

Pelvic exam in women:

Male exam:

Neurologic exam: perineal sensation (S2–S4), anal wink, bulbocavernosus reflex, lower-extremity strength and reflexes—abnormal findings demand neuroimaging and urology referral

Skin: check perineum and sacrum for moisture-associated dermatitis or early pressure injury in bedbound patients

Diagnostic Workup — Initial Labs and Bedside Studies

— Urinalysis ± culture: rule out UTI, glucosuria (uncontrolled DM causing osmotic diuresis), hematuria, proteinuria

— Post-void residual (PVR) by bladder scan or in-and-out catheterization within 10 min of voiding

· <50 mL: normal

· 50–200 mL: indeterminate, repeat or correlate clinically

· >200 mL or >¹⁄³ voided volume: suggests retention/overflow—avoid antimuscarinics, evaluate for obstruction

— Bladder diary (3 days): functional capacity, voids/day, nocturia, leak triggers, fluid intake

— Basic labs when clinically indicated: BMP (glucose, calcium, sodium, creatinine), HbA1c, TSH if polyuria; BUN/Cr before starting antimuscarinics or mirabegron

— Recurrent/persistent UTIs → renal/bladder US + PVR

— Suspected fistula → office dye test (oral phenazopyridine + tampon, or intravesical methylene blue) and pelvic MRI

— Suspected neurogenic bladder → MRI lumbosacral spine

Board pearl: A high PVR transforms management—anticholinergics are contraindicated in overflow incontinence because they worsen retention. If the stem mentions a palpable bladder, recent anticholinergic load, or PVR >200 mL, pivot to clean intermittent catheterization and treat the obstruction, not oxybutynin.

Every patient gets these four:

Hematuria workup: any microscopic hematuria ≥3 RBC/hpf in an adult without obvious benign cause → AUA pathway with cystoscopy and upper-tract imaging (CT urogram or renal US based on risk); gross hematuria is always abnormal

PSA in men: consider if BPH-related LUTS coexist and life expectancy >10 years, after shared decision-making (USPSTF C grade ages 55–69)

When to order more:

Avoid routine cystoscopy and urodynamics in uncomplicated stress, urge, or mixed UI before a trial of behavioral and first-line pharmacotherapy

Advanced and Confirmatory Studies

— Indications: failed empiric therapy, planned anti-incontinence surgery in complex cases, neurogenic bladder (spinal cord injury, MS, spina bifida), prior pelvic radiation, mixed symptoms with diagnostic uncertainty, men post-prostatectomy considering sling/AUS

— Components: uroflowmetry, filling cystometry (detrusor overactivity, compliance, capacity), pressure-flow study (obstruction vs underactivity), EMG, leak-point pressure

— Detrusor overactivity on cystometry = urge UI; Valsalva leak-point pressure <60 cm H₂O suggests intrinsic sphincter deficiency (impacts sling choice)

— Renal/bladder US: hydronephrosis, stones, residual volume, bladder wall thickening

— CT urogram: gold standard for upper tract evaluation in hematuria

— Pelvic MRI: complex prolapse, suspected fistula, neurologic etiology

— Defecography: when concurrent fecal incontinence or obstructed defecation

— Hematuria, recurrent UTI, abnormal neurologic exam

— Prior pelvic surgery/radiation, suspected fistula or mesh erosion

— POP beyond hymen, high PVR with unclear etiology

— Failure of two first-line therapies

— Pediatric or pregnant patients with new urinary symptoms

Step 3 management: Urodynamics is the wrong first move on a Step 3 stem—think behavioral therapy → drug → specialist → UDS. The classic distractor is "order urodynamic testing" for a clear-cut stress or urge picture; the correct answer is pelvic floor exercises or an antimuscarinic/β3-agonist trial first.

Urodynamic studies (UDS) — reserved, not routine:

Cystoscopy: indicated for hematuria, recurrent UTI, suspected bladder stones/tumor, fistula, prior mesh complications, sterile pyuria, or after pelvic radiation

Imaging:

Pad weight test: 1-hour or 24-hour pad weighing quantifies severity (>4 g/hr = significant) and tracks response objectively

Specialty referral triggers:

Risk Stratification and First-Line Management Logic

— Weight loss ≥5–10% in overweight women reduces stress UI episodes ~50%

— Fluid management: 1.5–2 L/day, reduce caffeine and alcohol, restrict evening intake 2–3 hours before bed

— Smoking cessation (chronic cough worsens stress UI)

— Bowel regimen: treat constipation to reduce pelvic floor strain

— Bladder training (urge UI): scheduled voiding starting at the diary interval, then increasing by 15–30 min weekly toward q3–4h

— Pelvic floor muscle training (Kegels): 3 sets of 8–12 contractions, 3×/day for ≥12 weeks; first-line for stress, urge, and mixed UI in women; also first-line for post-prostatectomy incontinence in men

— Prompted/timed voiding in cognitively impaired or frail elders

— Stress UI: no FDA-approved drug in the US; duloxetine used off-label in EU only. Mainstay = pelvic floor PT, pessary, or surgery

— Urge UI/OAB: antimuscarinic (oxybutynin, tolterodine, solifenacin, darifenacin, trospium, fesoterodine) OR β3-agonist (mirabegron, vibegron)

— Overflow: treat the cause—alpha-blocker ± 5-ARI in BPH; clean intermittent catheterization for detrusor underactivity

— Mixed: treat the predominant symptom first

— Atrophic UI: vaginal estrogen cream/ring/tablet (not systemic estrogen, which can worsen UI)

CCS pearl: On the CCS case, order the bladder diary, PVR, and UA on day 1, initiate pelvic floor exercises and lifestyle counseling the same visit, and schedule 6–12 week follow-up before reaching for drugs. Clock advancement before behavioral therapy = lost credit.

Tier 1 — Behavioral and lifestyle (offer to ALL patients, regardless of subtype):

Tier 2 — Pharmacotherapy (when behavioral therapy inadequate after 6–12 weeks)

Tier 3 — Procedures/devices (refractory or anatomic disease)

Subtype-directed first-line drug logic:

Pharmacotherapy — First-Line Drug Regimens

— Mechanism: M3 receptor antagonism on detrusor → ↓ involuntary contractions

— Options and notable features:

· Oxybutynin IR: cheapest, most anticholinergic SEs (dry mouth, constipation, blurred vision, cognitive impairment)

· Oxybutynin ER or transdermal patch: better tolerated

· Tolterodine, solifenacin, darifenacin, fesoterodine, trospium: more bladder-selective

· Trospium: quaternary amine → does not cross BBB → preferred in older adults with cognitive concerns

— Avoid in: narrow-angle glaucoma (uncontrolled), gastric retention, urinary retention, severe ulcerative colitis, myasthenia

— Counsel: full effect at 4–8 weeks; rotate agents if first fails

— Mirabegron, vibegron: relax detrusor during storage; no anticholinergic burden

— Preferred in elderly, dementia, or polypharmacy with high anticholinergic load

— Mirabegron caveats: monitor BP (can raise SBP ~2 mmHg), avoid uncontrolled HTN (>180/110); CYP2D6 interactions (metoprolol, desipramine)

— Vibegron: minimal BP effect, no major CYP interactions—emerging preferred β3

— Vaginal estrogen for GSM-associated symptoms

— Topical α-agonists not recommended

— α1-blockers (tamsulosin, alfuzosin, silodosin): onset within days; SEs—orthostasis, retrograde ejaculation, intraoperative floppy iris syndrome (hold before cataract surgery)

— 5α-reductase inhibitors (finasteride, dutasteride): for prostate >40 mL; 3–6 month onset; ↓ PSA by ~50%

Board pearl: In an 82-year-old with mild cognitive impairment and urge UI, mirabegron or vibegron beats oxybutynin every time—antimuscarinics carry FDA cognitive warnings and increase dementia risk per the Beers Criteria.

Urge UI / OAB — antimuscarinics:

Urge UI / OAB — β3-adrenergic agonists:

Combination antimuscarinic + β3-agonist for refractory OAB before third-line therapy

Stress UI adjuncts:

BPH/overflow:

Procedures and Device-Based Management

— Pelvic floor PT with biofeedback — first-line non-pharmacologic

— Continence pessary or urethral insert — for women preferring non-surgical option, poor surgical candidates, or pregnancy

— Midurethral sling (synthetic mesh, retropubic or transobturator) — gold-standard surgical cure rate ~80–90%; counsel about mesh complications (erosion, dyspareunia, voiding dysfunction)

— Autologous fascial sling — alternative if mesh contraindicated or after mesh failure

— Burch colposuspension — open or laparoscopic, used when concurrent abdominal surgery

— Urethral bulking agents — outpatient injection, less effective but minimally invasive

— Pelvic floor PT first (often resolves by 12 months)

— Male sling for mild–moderate persistent SUI

— Artificial urinary sphincter (AUS) — gold standard for moderate–severe SUI

— Intradetrusor onabotulinumtoxinA (100 U for idiopathic OAB, 200 U for neurogenic); risk of urinary retention requiring CIC ~6%

— Percutaneous tibial nerve stimulation (PTNS): 12 weekly 30-min sessions then maintenance

— Sacral neuromodulation (InterStim): implanted S3 lead; also treats fecal incontinence and non-obstructive retention

— TURP, photovaporization (GreenLight), prostatic urethral lift (UroLift), water vapor (Rezūm), simple prostatectomy for very large glands

— Intermittent catheterization > chronic indwelling (lower UTI, stone, cancer risk)

— Suprapubic > urethral for long-term needs

Step 3 management: Always exhaust behavioral therapy + ≥2 drug trials before sending a patient for Botox or neuromodulation. Surgery for stress UI is appropriate after a documented PFMT trial unless the patient declines conservative therapy.

Stress UI procedures (women):

Stress UI in men (post-prostatectomy):

Refractory OAB / urge UI — third-line therapies (after failed behavioral + 2 drug classes):

Overflow / BPH procedures:

Catheter management:

Special Populations — Elderly and Renal/Hepatic Impairment

— Always screen for DIAPPERS before adding drugs

— Review anticholinergic burden (ACB scale): TCAs, first-gen antihistamines, oxybutynin, paroxetine, scopolamine; total ACB ≥3 raises dementia and fall risk

— Beers Criteria: avoid oxybutynin IR; prefer trospium, darifenacin, mirabegron, or vibegron

— Vision, dentition (dry mouth tolerability), hydration status, fall risk

— Prompted voiding every 2 hours during the day is first-line

— Avoid chronic indwelling catheters except for stage 3–4 pressure injury, palliative comfort, or urinary retention not amenable to CIC

— Address functional UI: bedside commode, raised toilet seat, Velcro clothing, adequate lighting, mobility aids

— Trospium: reduce to 20 mg daily if CrCl <30; avoid IR if CrCl <15

— Solifenacin: max 5 mg if CrCl <30

— Fesoterodine: max 4 mg if CrCl <30

— Mirabegron: max 25 mg if eGFR 15–29; avoid in ESRD

— Darifenacin: dose adjust in hepatic impairment, not renal

— Mirabegron: avoid in Child-Pugh C; max 25 mg in Child-Pugh B

— Solifenacin: max 5 mg in moderate hepatic impairment; avoid in severe

— Tolterodine, fesoterodine: dose reduce in hepatic impairment

— Loop diuretic dosed at bedtime → nocturia (move to morning)

— Donepezil + oxybutynin = pharmacologic tug-of-war, worsens both cognition and UI

— SGLT2 inhibitors → osmotic diuresis and GU infections mimicking UI flare

Board pearl: A 79-year-old woman on oxybutynin who develops confusion and falls is anticholinergic toxicity until proven otherwise—stop the drug, reassess in 2–4 weeks, and switch to mirabegron or trospium if pharmacotherapy is still needed.

Geriatric core principles:

Frail elders and nursing home residents:

Renal impairment:

Hepatic impairment:

Polypharmacy traps:

Special Populations — Pregnancy, Postpartum, and Other Subgroups

— Up to 40% of pregnant women experience stress UI from increased intra-abdominal pressure and progesterone-mediated urethral relaxation

— First-line: antenatal pelvic floor muscle training reduces both antenatal and postpartum incontinence (Level A evidence)

— Avoid antimuscarinics and mirabegron in pregnancy (limited safety data); defer surgery until childbearing complete

— Postpartum: most stress UI improves within 12 months; persistent symptoms at 3 months warrant PT referral

— Mode of delivery: vaginal delivery raises stress UI risk vs cesarean, but cesarean is not recommended solely for continence preservation

— Spinal cord injury above T6: risk of autonomic dysreflexia with bladder distension—emergency, sit patient up, drain bladder, treat HTN

— Suprapontine lesion (stroke, Parkinson, MS): detrusor overactivity → urge UI

— Sacral/cauda lesion: detrusor areflexia → overflow; needs CIC

— Multidisciplinary management with urology, physiatry, urodynamics every 1–2 years

— Counsel preoperatively that some leakage is expected; ~90% continent by 12 months

— Pelvic floor PT begun preoperatively

— Toileting routines, prompted voiding, caregiver education

— Avoid antimuscarinics; mirabegron preferred if drug needed

— Post–gender-affirming surgery patients may have unique anatomy; refer to specialty pelvic floor PT

Key distinction: In pregnancy, PFMT is the only universally safe first-line therapy. Avoid the trap of starting an antimuscarinic for a pregnant patient with urge symptoms—rule out UTI and refer for behavioral therapy.

Pregnancy and postpartum:

Neurogenic bladder:

Post-prostatectomy:

Pediatric/adolescent enuresis (rarely on Step 3): rule out UTI, constipation, diabetes; bedwetting alarms first-line; desmopressin second

Cognitively impaired adults:

LGBTQ+ and gender-affirming considerations:

Complications and Adverse Outcomes

— Skin breakdown: moisture-associated dermatitis, candidal intertrigo, sacral pressure injury in immobile patients—prevent with barrier creams, frequent changes, low-air-loss surfaces

— Recurrent UTIs: especially with high PVR or chronic catheter; treat per IDSA; consider prophylactic vaginal estrogen in postmenopausal women

— Falls and fractures: rushing to toilet, especially nocturia—major driver of hip fracture in elderly; address nocturia aggressively

— Sleep deprivation and depression: nocturia ≥2 doubles depression risk

— Sexual dysfunction: coital incontinence in 10–25% of women with UI

— Upper tract damage: chronic high-pressure retention or neurogenic bladder can cause hydronephrosis and CKD—monitor creatinine and renal US

— Antimuscarinics: dry mouth, constipation, blurred vision, urinary retention, cognitive impairment/dementia risk, tachycardia, heat intolerance

— Mirabegron: hypertension, headache, rare angioedema

— α-blockers: orthostatic hypotension (falls), floppy iris syndrome, retrograde ejaculation

— Midurethral sling: mesh erosion (~2–3%), de novo urgency, voiding dysfunction, dyspareunia, chronic pelvic pain

— Botox: UTI, urinary retention requiring CIC (6–10%), hematuria

— Sacral neuromodulation: lead migration, infection, pain at site, need for revision

— AUS: mechanical failure, erosion, infection, atrophy of urethra

— Social isolation, work absenteeism, caregiver burnout

— Nursing home placement: UI is among top 3 reasons for institutionalization

CCS pearl: When managing UI in the elderly, always include skin assessment and fall-risk counseling as separate orders. Missing these on a frail-elder case costs credit even when the bladder regimen is correct.

Direct medical complications:

Drug-related complications:

Procedural complications:

Psychosocial:

When to Escalate Care — Referral and Inpatient Triggers

— Hematuria (gross or microscopic in adults at risk)

— Persistent or recurrent UTIs (≥2 in 6 months or ≥3 in 12 months)

— High post-void residual (>200–300 mL) or palpable bladder

— Suspected fistula (continuous leakage after pelvic surgery, delivery, or radiation)

— Pelvic organ prolapse beyond the hymen

— Pelvic pain, suspected mesh complication, prior failed anti-incontinence surgery

— Neurologic signs suggesting cord compression or cauda equina—this is an emergency

— Failure of two adequate trials of first-line pharmacotherapy

— Consideration of Botox, neuromodulation, or surgery

— Acute urinary retention: immediate catheterization, U/A, BMP; admit if AKI, urosepsis, or inability to manage CIC at home

— Urosepsis: sepsis bundle, broad-spectrum antibiotics, source control (relieve obstruction, remove infected stone or catheter)

— Cauda equina syndrome: STAT MRI lumbar spine, neurosurgical consult—do not wait

— Autonomic dysreflexia in SCI patient with distended bladder: sit upright, immediate bladder drainage, antihypertensive (nitrate, nifedipine) if SBP >150

— Obstructive uropathy with AKI or hydronephrosis: percutaneous nephrostomy or retrograde stent

— Pelvic floor physical therapy (often the highest-yield single referral)

— Geriatrics or memory clinic if cognitive concerns drive functional UI

— Wound care for severe perineal dermatitis or sacral injury

— Behavioral health for depression or coital-incontinence-related distress

Step 3 management: A new neurologic deficit (saddle anesthesia, lower extremity weakness, bowel incontinence) with urinary symptoms = STAT MRI and neurosurgery consult. Do not order urodynamics, do not start oxybutynin—this is a red-flag presentation that costs many points if missed.

Refer to urology or urogynecology urgently/expeditiously when:

Emergency department / inpatient triage:

Multidisciplinary input:

Key Differentials — Same-Category (Urinary) Causes

— Sudden onset urgency, dysuria, frequency; pyuria and bacteriuria

— Always rule out before labeling chronic OAB

— Painless gross hematuria, irritative symptoms, smoker, occupational exposure (aromatic amines, rubber, dyes), age >40

— Workup: cystoscopy + CT urogram + urine cytology

— Urgency/frequency with pain relieved by voiding, sterile urine, often in women 30–50

— Diagnosis of exclusion; hydrodistension, pentosan polysulfate, amitriptyline

— Hesitancy, weak stream, intermittency, post-void dribbling, nocturia in men >50

— Treat with α-blocker ± 5-ARI; surgical options if refractory

— Diabetes mellitus, diabetes insipidus (central or nephrogenic), psychogenic polydipsia, primary nocturnal polyuria of aging, OSA-driven nocturia, CHF-driven nocturia, hypercalcemia

Key distinction: Painful urgency with sterile urine = think interstitial cystitis. Painless urgency = OAB/urge UI. Painless gross hematuria in any adult = cancer until proven otherwise, regardless of LUTS pattern.

Urinary tract infection / cystitis:

Bladder cancer:

Bladder stones: intermittent stream, terminal hematuria, recurrent UTI; KUB or CT

Interstitial cystitis / bladder pain syndrome:

Benign prostatic hyperplasia / bladder outlet obstruction:

Urethral stricture: trauma, instrumentation, STI history; weak stream, retention; retrograde urethrogram

Pelvic organ prolapse: sensation of bulge, splinting to void, stress or overflow component

Urethral diverticulum: post-void dribbling, dyspareunia, anterior vaginal mass, tender on exam; MRI confirms

Genitourinary syndrome of menopause: dryness, dyspareunia, urgency, recurrent UTI; treat with vaginal estrogen

Vesicovaginal/ureterovaginal fistula: continuous leakage after pelvic surgery, childbirth, or radiation; dye test, cystoscopy

Diabetic cystopathy: detrusor underactivity from autonomic neuropathy → overflow

Polyuria states:

Key Differentials — Non-Urinary Mimics

— Stroke: urge UI with detrusor overactivity, often functional component

— Parkinson disease and multiple system atrophy: nocturia, urge UI; MSA causes earlier severe UI than idiopathic PD

— Multiple sclerosis: detrusor overactivity ± detrusor-sphincter dyssynergia

— Normal pressure hydrocephalus: wet, wacky, wobbly (urinary incontinence, dementia, gait apraxia)

— Spinal cord lesions: MS plaques, tumor, herniation, cauda equina, transverse myelitis

— Diabetic autonomic neuropathy: detrusor underactivity, overflow

— Pudendal nerve injury (cycling, childbirth)

— Uncontrolled diabetes (osmotic diuresis), diabetes insipidus, hypercalcemia, hyperthyroidism with frequency, hypokalemia with nephrogenic DI

— CHF—nighttime mobilization of edema causes nocturia; treat heart failure rather than the bladder

— OSA—nocturnal hypoxia raises ANP and produces nocturnal polyuria; CPAP often resolves nocturia

— Chronic cough (COPD, ACE inhibitor, asthma) exacerbates stress UI

— Diuretics (timing matters—dose in morning)

— α-blockers in women (relax urethra → SUI)

— Cholinesterase inhibitors (donepezil, rivastigmine) → urge UI

— SSRIs, lithium, gabapentinoids → various effects

— SGLT2 inhibitors → osmotic polyuria, GU infections

— Alcohol, caffeine → diuresis and detrusor irritation

— Depression and anxiety amplify symptom perception

— Dementia → functional UI from inability to recognize/locate toilet

Board pearl: A patient with gait apraxia + dementia + new UI is NPH—order brain MRI and consider large-volume LP / shunt evaluation, not an antimuscarinic. The "wet, wacky, wobbly" triad is a frequent Step 3 trap because the UI is the most prominent complaint.

Neurologic causes of incontinence:

Endocrine and metabolic:

Cardiopulmonary:

Pharmacologic mimics:

Psychiatric / functional:

Gynecologic: uterine fibroids causing pressure-related frequency; ovarian mass

Secondary Prevention and Long-Term Plan

— Lifelong pelvic floor exercises—gains regress without maintenance

— Continued bladder diary at flares to identify new triggers

— Annual reassessment of fluid intake, caffeine, alcohol, weight

— Reassess every 4–12 weeks initially; deprescribe if no benefit at 8–12 weeks

— Rotate antimuscarinics before declaring failure

— Consider drug holidays in stable patients to test ongoing need

— Annual review of anticholinergic burden in elderly

— Diabetes: target A1c per individualized goals to reduce osmotic diuresis

— CHF: optimize diuresis timing (morning loop, compression stockings, evening leg elevation)

— OSA: CPAP—often resolves nocturia

— Constipation: fiber, hydration, osmotic laxative; reassess incontinence after bowel regimen

— Cough: treat asthma/COPD, stop ACE inhibitor if appropriate

— Estrogen deficiency: ongoing vaginal estrogen for postmenopausal GSM

— Pessary: clean and reposition every 1–3 months; vaginal estrogen reduces erosion

— Sling: annual check for mesh exposure, dyspareunia, voiding dysfunction

— Botox: repeat every 6–9 months; check PVR after each injection

— Sacral neuromodulation: device interrogation per programming schedule; MRI compatibility counseling

— CIC > indwelling; teach clean technique; supply prescriptions

— Indwelling: change every 4 weeks, suprapubic preferred long-term

— Do not treat asymptomatic bacteriuria in catheterized patients

Step 3 management: Asymptomatic bacteriuria in a chronically catheterized or elderly patient is not treated—doing so breeds resistance and C. diff. Treat only if true UTI symptoms (fever, suprapubic pain, hematuria, acute mental status change with no other source).

Sustaining behavioral gains:

Pharmacotherapy stewardship:

Comorbidity optimization (the "treat the cause" list):

Device and surgical follow-up:

Catheter care:

Follow-Up, Monitoring, and Counseling

— Initial follow-up at 4–6 weeks after starting behavioral therapy or new drug to assess response and side effects

— 3-month formal reassessment with repeat bladder diary; if <50% reduction in leak episodes, escalate

— Every 6–12 months thereafter once stable

— Antimuscarinics: dry mouth, constipation, vision, cognition (MoCA in elders), heart rate, PVR if symptoms suggest retention

— Mirabegron/vibegron: blood pressure at each visit; mirabegron contraindicated with severe uncontrolled HTN

— α-blockers: orthostatic vitals, sexual side effects, pre-op pause before cataract surgery

— 5-ARIs: PSA (halve interpretation), libido, gynecomastia

— Botox: PVR at 2 and 4 weeks post-injection

— Pessary: pelvic exam every 1–3 months

— Validated questionnaires: ICIQ-UI SF, IIQ-7, UDI-6, OAB-q

— Pad count, bladder diary trends, quality-of-life metrics

— Realistic expectations: improvement >> cure; 50% reduction is a clinical win

— Self-management resources: NAFC, voiding diary apps

— Sexual health: address coital incontinence explicitly

— Mental health: screen with PHQ-2/PHQ-9; treat depression

— Caregiver education: prompted voiding, skin care, fall prevention

— Discharge after Botox or sling: clear instructions for retention symptoms, when to seek care

— Nursing home transfer: send updated medication list, toileting schedule, continence supplies plan

CCS pearl: Build the case with scheduled follow-up at 6 weeks, repeat U/A and PVR, and a fall-risk + skin assessment baked in. Forgetting the 3-month bladder diary recheck is a common credit loss on management-heavy CCS cases.

Visit cadence:

Monitoring parameters by therapy:

Outcomes tracking tools:

Counseling priorities:

Care transitions:

Ethical, Legal, and Patient Safety Considerations

— Document discussion of mesh erosion, dyspareunia, chronic pain, need for revision

— FDA reclassified transvaginal mesh for prolapse as high-risk; midurethral slings for SUI remain standard of care—differentiate clearly during counseling

— Provide written materials; revisit decision after a cooling-off period

— Patient may lack capacity for surgical decisions but retain capacity for daily toileting preferences

— Engage healthcare proxy and align with prior values; document

— In end-of-life or advanced dementia, comfort-focused continence care (good skin care, dignified products) may be preferable to aggressive workup—document the conversation

— Document review of ACB score and rationale for choosing each agent

— Reconcile medications at every visit; deprescribe aggressively

— Document indication for every catheter daily in hospitalized patients; remove ASAP

— National patient-safety quality metric; CMS does not reimburse hospital-acquired CAUTI

— UI in an adult with new bruising, dehydration, or fecal impaction → consider elder abuse or neglect and report to Adult Protective Services

— Pediatric UI with concerning physical findings → mandated child-abuse reporting

— Botox patients discharged without retention precautions and CIC education

— Sling patients without urinary retention warning

— Discontinuation of vaginal estrogen at hospital admission—reconcile and resume

— Continence products often not covered by Medicare Part B; counsel patients on cost

— Address barriers to pelvic floor PT in rural areas via telehealth

Board pearl: A bedridden elder with new perineal dermatitis, dehydration, and unexplained injuries warrants APS notification—this is the Step 3 ethics layer hiding inside a "geriatric incontinence" stem.

Informed consent for mesh and surgical devices:

Decisional capacity in cognitively impaired patients:

Goals-of-care alignment in frail elders:

Patient safety: anticholinergic burden and falls:

Catheter-associated UTI (CAUTI) prevention:

Mandatory reporting:

Transition-of-care risks:

Health-systems and equity:

High-Yield Associations and Rapid-Fire Facts

Step 3 management: When in doubt on a stem: diary + UA + PVR + behavioral therapy is rarely the wrong first answer.

Stress UI ↔ multiparity, vaginal delivery, obesity, chronic cough, hysterectomy, post-prostatectomy, intrinsic sphincter deficiency

Urge UI / OAB ↔ aging, stroke, MS, Parkinson, bladder outlet obstruction, idiopathic detrusor overactivity

Overflow ↔ BPH, diabetic cystopathy, anticholinergic burden, post-op urinary retention, spinal cord lesion below S2

Functional UI ↔ dementia, severe arthritis, restraints, inaccessible toilet

Continuous leak after pelvic surgery/childbirth/radiation = fistula

"Wet, wacky, wobbly" = normal pressure hydrocephalus

DIAPPERS mnemonic for reversible causes

Cough stress test positive + urethral hypermobility = stress UI, skip urodynamics

PVR >200 mL = retention/overflow → avoid antimuscarinics

Painless gross hematuria = bladder cancer until proven otherwise (CT urogram + cystoscopy)

First-line behavioral interventions work for all subtypes—offer to everyone

Pelvic floor PT is first-line for stress, urge, mixed UI in women and post-prostatectomy UI in men

Weight loss ≥5–10% halves SUI episodes

Vaginal estrogen = preferred for GSM-related UI; systemic estrogen worsens UI

Mirabegron/vibegron preferred over antimuscarinics in elderly

Trospium = quaternary amine, does not cross BBB → cognitively safer

Oxybutynin IR = Beers Criteria avoid in elderly

No FDA-approved drug for stress UI in the US

Tamsulosin → intraoperative floppy iris syndrome → hold before cataract surgery

Botox for refractory OAB → check PVR; 6–10% need CIC

Sacral neuromodulation treats OAB, non-obstructive retention, and fecal incontinence

AUS = gold standard for severe post-prostatectomy SUI

Asymptomatic bacteriuria in chronic catheter or elder = do NOT treat

Nocturia → check CHF, OSA, diabetes, diuretic timing, evening fluid intake

Sleep apnea + nocturia → CPAP often cures

5-ARIs halve PSA—double measured value for cancer screening

Board Question Stem Patterns

Key distinction: The wrong-answer magnet across nearly every UI stem is "order urodynamics" or "refer for surgery" too early. The right answer almost always starts with diary, UA, PVR, and behavioral therapy.

Pattern 1 — Classic stress UI: 52-year-old multiparous woman leaks with coughing/laughing; exam shows mild cystocele and positive cough stress test → Answer: pelvic floor muscle training (not urodynamics, not sling first)

Pattern 2 — OAB in elderly: 78-year-old woman with sudden urgency and 2 leaks/day, no infection → Answer: bladder training + mirabegron (not oxybutynin given age)

Pattern 3 — Reversible cause: Nursing home resident with new incontinence and confusion → Answer: urinalysis (DIAPPERS—UTI first)

Pattern 4 — Overflow trap: Diabetic man with dribbling, palpable bladder, PVR 450 mL → Answer: catheterization and evaluate obstruction, NOT antimuscarinic

Pattern 5 — Anticholinergic toxicity: Older woman on oxybutynin with new confusion and falls → Answer: discontinue oxybutynin, consider mirabegron

Pattern 6 — Fistula: Continuous leakage after recent hysterectomy → Answer: methylene blue/dye test or cystoscopy, refer to urogynecology

Pattern 7 — Bladder cancer red flag: 65-year-old smoker with urgency and microscopic hematuria → Answer: cystoscopy + CT urogram, not "treat OAB empirically"

Pattern 8 — NPH triad: Older man with gait apraxia, dementia, and incontinence → Answer: brain MRI and consider large-volume LP

Pattern 9 — Cauda equina: Saddle anesthesia, urinary retention, leg weakness → Answer: STAT MRI lumbar spine + neurosurgery

Pattern 10 — Post-prostatectomy SUI: 6 months post-RP, persistent leakage → Answer: pelvic floor PT first; AUS only after ≥12 months

Pattern 11 — GSM-related symptoms: Postmenopausal woman with urgency, dyspareunia, recurrent UTI, atrophic exam → Answer: vaginal estrogen

Pattern 12 — Nocturia in CHF: Worsens with evening furosemide dosing → Answer: shift diuretic to morning

Pattern 13 — Mesh complications: Dyspareunia and vaginal mass after sling → Answer: refer to urogynecology, do not excise blindly

Pattern 14 — Refractory OAB: Failed two antimuscarinics + behavioral therapy → Answer: intradetrusor Botox, PTNS, or sacral neuromodulation

One-Line Recap

Urinary incontinence is a syndrome, not a disease—classify the subtype, rule out reversible DIAPPERS causes and red flags, layer behavioral therapy first for everyone, and escalate to subtype-targeted drugs, devices, or surgery only when conservative measures fail.

— Stress UI → PFMT, weight loss, pessary, midurethral sling (no FDA-approved US drug)

— Urge UI/OAB → bladder training + β3-agonist (mirabegron/vibegron) preferred over antimuscarinic in elderly; Botox/SNM for refractory disease

— Overflow → relieve obstruction (α-blocker, 5-ARI, surgery) or CIC for detrusor underactivity; antimuscarinics contraindicated

— Mixed → treat the predominant symptom

— Functional → toileting schedule, environmental modification, caregiver support

— Atrophic/GSM-related → vaginal (not systemic) estrogen

Board pearl: When stuck on any Step 3 UI question, default to "diary + UA + PVR + behavioral therapy"—it is the right first move in well over 80% of stems and the foundation on which every drug, device, and surgery is layered.

Workup mantra: bladder Diary + Urinalysis + Post-void residual + targeted exam (cough stress test, pelvic, neuro) — almost no one needs urodynamics or cystoscopy on the first visit

Subtype-to-treatment cheat sheet:

Red flags that bypass the algorithm: hematuria, recurrent UTI, neurologic deficits, high PVR, suspected fistula, prior pelvic radiation, pelvic organ prolapse beyond hymen, cauda equina signs, NPH triad—refer or image immediately

Geriatric overlay: screen DIAPPERS, minimize anticholinergic burden, prevent falls and skin breakdown, align therapy with goals of care, never treat asymptomatic bacteriuria